Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2026 · 10-Q
Revenue$444.00K$444.00K+13.6% vs Q2 2025 Net Income-$785.00K-$785.00KN/M vs Q2 2025 EPS Diluted-$0.01-$0.01N/M vs Q2 2025 Gross Profit$238,000+4.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$606,000N/M Margins · derivedGross margin53.6%−4.5 pt vs Q2 2025
Operating margin-153.8%+31.6 pt vs Q2 2025
Net margin-176.8%+27.3 pt vs Q2 2025
ended Jan 31, 2026 · filed Mar 17, 2026 · 45 d after period end